Please login to the form below

Not currently logged in

ImmunoGen hires VP product strategy

Eric Guempel joins from Merck Serono

ImmunoGen has appointed Eric Guempel as the company's first VP of product strategy and programme management.

Guempel joins from Merck Serono where he served as head of new therapies and strategy for the company's oncology business.

His previous business experience includes several oncology-related positions at Biogen Idec, including team leader for Rituxan (rituximab), as well as commercial positions at Amgen,

Guempel's career also includes research-related positions at Amgen, Berlex and Ciba-Geigy (now Novartis).

Dr Charles Morris explained the creation of Guempel's new role.

“Eric joins ImmunoGen in a new position we established to enhance the strategic leadership of our proprietary programmes, ensuring that as we advance our clinical compounds through proof of concept we implement development strategies for each compound that align with patient and market needs,” said Dr Morris.

These programmes focus on antibody-drug conjugates (ADCs) to target cancers.

The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

3rd February 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...